CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

Size: px
Start display at page:

Download "CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA"

Transcription

1 CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA

2 Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR brachytherapy and IMRT are as good as those reported for RP series This is a result of improved technology and technical improvements by practitioners Data on dose response relationships of LDT and HDR brachytherapy, 3D-CRT and IMRT are now fairly well defined Thus, the goal of therapy is now one of delivering an ablative course of therapy In addition, the technological improvements have also resulted in reduced morbidity of therapy

3 Goals for CyberKnife Therapy for CaP Emulate success of HDR brachytherapy tumor control Hypofractionation schemes Low alpha/beta ratio for prostate cancer Equivalent BED values Reduce complications Need low toxicities for urinary, rectal and sexual function Need high accuracy and & motion compensation Need for high conformality Maintain quality of life Minimally invasive Shorter treatment times Outpatient procedure No indwelling catheter

4 Proposed Prostate Alpha/Beta Ratios Brenner DJ (JROBP 1999:43, ) Data: EBRT and LDR brachytherapy Alpha/Beta: 1.5 Brenner DR (IROBP 2002: 52, 6-13 ) Data: EBRT and HDR brachytherapy Alpha/Beta: 1.2 Fowler JF ( JROBP 2003: 56, ) Data: hypofractionated EBRT Alpha/Beta: 1.5

5 DOSE CALCULATION If Alpha/BETA Ratio for Prostate Cancer is 1.5 Then We Are Delivering B.E.D. of cgy at 180/fx

6 Alpha / Beta Ratios Moderate ( 4-5 ) range: Late responding tissues Some sensitivity to fractionation EQUIVALENT DOSE TO RECTUM AND BLADDER 70-73GY High (8-10 ) range: Acute responding tissues Little sensitivity to fractionation

7 Effectiveness and Applicability of CK CK monotherapy: Low risk and low intermediate risk CaP EBRT + CK boost: High risk and high intermediate risk Cap Basically, CK reproduces dose distributions very much like HDR, except more homogeneous and non-invasively May reduce the need for androgen deprivation therapy (ADT) for volume reduction or some patients with more extensive disease

8

9 CYBERKNIFE 1. Ability to track prostate motion using fiducial seeds 2. Non -Coplanar and non Iso-centric Beams delivered by a linac mounted on a robotic arm 3. Ability to use smaller margins to limit dose to penile bulb and neuro vascular bundles

10 STEREOTACTIC RADIOSURGERY FOR LOCALIZED PROSTATE CA KATZ,A SANTORO,M ET AL BMC UROLOGY FEB 2010

11 STEREOTACTIC RADIOSURGERY AS A BOOST TO EBRT FOR INTERMEDIATE AND HIGH RISK EARLY PROSTATE CANCER KATZ,A SANTORO M et al TCRT December 2010

12 Basic Demographics All Patients with Stage ct1cnomo or T2A Minimum 30 month follow up,median 48 All patients treated between 4/5/2006 and 01/15/2010 Total number of Patients = 591 All patients treated by 1 Urologist and 1 Radiation Oncologist

13 Histology Gleason grade = 362 Patients Gleason grade 7 = 165 Patients Gleason grade >4+3 = 64 Patients

14 Prostate Volumes Range = 21.2cc to 150 cc Mean initial volume = 48.2 cc Median initial volume = 46.1 cc

15 Initial PSA s Range = 1.1 to 52.3 ng/ml Mean initial PSA = 7.78 ng/ml Median initial PSA = 5.1 ng/ml N= 591

16 PRESCRIBED DOSE MONOTHERAPY 515 patients 158 received 700 CGY X received 725 cgy x 5 PROSTATE +- SEMINAL VESICLES WITH 5MM MARGIN (3 posteriorly)

17 35Gy used on low risk and low intermediate risk patients used on all risk groups

18 PATIENT CHARACTERISTICS Prospective trial of 515 patients for monotherapy 463 with T1c, 52 with T2a 343 low-risk, 134 intermediate-risk, & 38 high-risk Mean age 69.2 years Mean PSA 6.08 ng/ml No restrictions on volume, AUA score or # of cores 67 patients received ADT for < 3 months 28 patients died of other causes 23 lost to follow-up All patients had CT and MR for treatment planning

19 PRESCRIBED BOOST DOSE INTERMEDIATE TO HIGH RISK 76 Patients 4500 CGY TO PELVIS PLUS BOOST CGY X 3 PROSTATE WITH CYBERKNIFE SRRS

20

21 TREATMENT PLANNING CT AND MRI FOR VOLUME LOCALIZATION PLANNING BLADDER AND RECTUM IDENTIFIED ALONG WITH PROSTATE & SV CLEAN OUT PRIOR TO SCANS AND RX

22 CT/MR

23 CT/MR

24 MRI Better definition of prostate Decrease GTV by up to 25% Helps decrease penile bulb dose

25 PRESCRIPTION DOSE Prescribe to the 83-87% line to cover the PTV Cover 95% of the PTV with prescription Dose This is known as homogeneous planning

26 PROSTATE PLAN

27

28 IRIS COLLIMATOR USES >6 COLLIMATOR SIZES IMPROVES DVH TO BLADDER AND RECTUM BY 25-30% SPEEDS UP TREATMENT TIME BETTER DVH LEADS TO LESS ACUTE RECTAL TOXICITY GRADE1 IS ONLY 36% WITH IRIS NO NEED FOR AMIFOSTINE

29

30 Testis Dose Average cgy Similar to IMRT No effect on testosterone No effect on PSA decline Can be diminished by avoiding beams through the testes

31 LOCALIZATION ALL PATIENTS RECEIVE 4 FIDUCIAL MARKERS PLACED UNDER ULTRASOUND GUIDANCE

32 FIDUCIAL PLACEMENT 1. LOCAL ANESTHETIC WITH EMLA CREAM AND SQ LIDOCAINE 2. 2 SEEDS AT BASE 3. 2 SEEDS AT APEX 4. SEEDS TRACKED FOR TRANSLATION, ROTATION AND PITCH

33

34

35

36 FIDUCIAL LOCALIZATION

37 TREATMENT 40 MM COLLIMATOR AND 25 MM COLLIMATOR BEAMS 45 MINUTES

38 TOXICITY FOR MONOTHERAPY

39 ACUTE URINARY TOXICITY 78% - GRADE 1 4% GRADE 2 ALL BACK TO BASELINE AT 3 MONTHS

40 ACUTE RECTAL TOXICITY 82% - GRADE Ι 4% - GRADE II ALL BACK TO BASELINE AT 3 MONTHS

41 LATE TOXICITY percent 2% 9% percent 4% 6% 8% 4% All toxicity occurred 3 years post-treatment Potency preserved for 78% of patients at 4 years

42 Late Toxicity For 515 patients, the difference in late urinary toxicity between 35 and Gy is statistically significant p<0.01

43 EPIC QUALITY of LIFE Bowel Urinary EPIC Score Gy Gy Months Sexual

44

45 ED RATES 78% For Monotherapy 66% For Boost Penile Bulb Dose < 18 GY

46

47

48 MONOTHERAPY FIVE YEAR BIOCHEMICAL EFFICACY To be reported at ASTRO along with 600 more patients from 7 institutions

49

50

51 MONOTHERAPY 100% Local Control and 97.5% Freedom from PSA failure for low risk For Intermediate Risk patients 99% Local control 92% Freedom from failure

52 AUA Patients with intermediate risk disease

53

54

55 High Risk Monotherapy 77%Biochemical control at 36 months median (9/38) 8% local Failure(3 pts)

56 35 vs Gy PSA nadirs and control are equal (See Katz et al Frontiers in Oncology Nov. 2011) Urinary toxicity worse for p< Gy=90-91 Gy at 180/fx or BED of198 This is probably on the flat part of the dose response curve and higher dose would not be expected to improve control

57

58 OTHER DOSE SCHEMES Meier 40GY(to GTV) p/5fx Daily Fuller 38Gy/4 fx Daily Timmerman(non CK) 50 Gy/ 5fx QOD King Gy/5 fx QOD

59 BOOST THERAPY 5 Year EFFICACY REPORTED at ESTRO 2012 In line with HDR as a boost results

60

61

62

63 CK Mono vs. Boost 44 Intermediate risk pts monotherapy 37 Intermediate risk pts- CK as boost No Hormones More rectal toxicity in boost group Presented at ESTRO Katz, Santoro et al

64 Biochemical failure occurred in 2/35 boost patients and 2/44 monotherapypatients; biochemical control rates were 94.3% and 95.5%, respectively.

65 BOOST vs MONO

66 STANFORD NAPLES 42 pts treated with CK Mono 5 year followup 94% Biochemical control

67 McGill Trial 66Gy in 22fx 3D Conformal 2.5% biochemical failures, same as CK BED 90 Gy 33% late grade 2 GU Toxicity 28% late grade 2 GI Toxicity

68 Archangeli Trial 3.1 Gy x 20 superior to 2y x 40 for intermediate and high risk patients Supports alpha/beta of 1.5

69 WHY NOT STOP at FRACTIONS? IS 5 FRACTIONS BETTER?

70 Dose to tumor vs normal tissue Dose BED to prostate normal 7x x x

71 SUMMARY 5 Year results show high efficacy,low toxicity and ED and low cost(22k) PSA results mimic HDR Brachytherapy, which has very high control rates at 10 years Need for more followup to confirm but very low PSA nadirs are encouraging Sexual and Urinary QOL better than surgery

72 SUMMARY 35 GY seems to be optimal dose for low and low intermediate risk patients. PSA results equal to Gy or 38GY heterogeneous No need for ADT No need for EBRT IRIS Collimator yields less rectal toxicity and is highly recommended Consider internal boost for higher risk patients

73 icad MRI

74 Heterogeneous Plan

75 FOR THE FUTURE DOSE PAINTING FEWER FRACTIONS 9.5x3 BED = 90 Gy 19 x1 Munich

Stereotactic Body Radiation Therapy for Prostate Cancer

Stereotactic Body Radiation Therapy for Prostate Cancer Stereotactic Body Radiation Therapy for Prostate Cancer Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University

More information

Implementation Date: April 2015 Clinical Operations

Implementation Date: April 2015 Clinical Operations National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:

More information

Radiation Therapy for Prostate Cancer: Treatment options and future directions

Radiation Therapy for Prostate Cancer: Treatment options and future directions Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment

More information

Predictors of toxicity in single fraction prostate HDR with EBRT. Dr Gail Tsang

Predictors of toxicity in single fraction prostate HDR with EBRT. Dr Gail Tsang Predictors of toxicity in single fraction prostate HDR with EBRT Dr Gail Tsang Methods Fellowship, Sunnybrook Hospital, Toronto Single institutional, prospective study Intermediate risk prostate cancer

More information

Advances in Brachytherapy for Prostate Cancer

Advances in Brachytherapy for Prostate Cancer Advances in Brachytherapy for Prostate Cancer Michael J Zelefsky M.D Professor of Radiation Oncology Chief, Brachytherapy Service Vice Chair Clinical Research Memorial Sloan Kettering Cancer New York,

More information

Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.

Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D. Protons vs. CyberKnife UC SF Protons vs. CyberKnife UC SF Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University

More information

Introduction to Prostate Brachytherapy. Wayne Butler, PhD Schiffler Cancer Center Wheeling Hospital

Introduction to Prostate Brachytherapy. Wayne Butler, PhD Schiffler Cancer Center Wheeling Hospital Introduction to Prostate Brachytherapy Wayne Butler, PhD Schiffler Cancer Center Wheeling Hospital Prostate Cancer Death Rate (American Cancer Society 25) 45 Death Rate per 1, Men 4 35 3 25 2 15 1 5 193

More information

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials

More information

Clinical Applications of Brachytherapy

Clinical Applications of Brachytherapy Clinical Applications of Brachytherapy Yoshiya(Josh) Yamada MD FRCPC Department of Radiation Oncology Memorial Sloan Kettering Cancer Center Disclosures Institute for Medical Education Speakers Bureau

More information

PROSTATE AND NORMAL TISSUE CONSTRAINTS TO OPTIMIZE PROSTATE HDR BRACHYTHERAPY

PROSTATE AND NORMAL TISSUE CONSTRAINTS TO OPTIMIZE PROSTATE HDR BRACHYTHERAPY PROSTATE AND NORMAL TISSUE CONSTRAINTS TO OPTIMIZE PROSTATE HDR BRACHYTHERAPY Alvaro Martinez, MD, FACR Professor Of Radiation Oncology Oakland University William Beaumont School of Medicine Senior VP

More information

PROSTATE CANCER: LOCAL CONTROL, SURVIVAL AND HIGH DOSE RADIATION THERAPY. Riccardo Santoni. Radiation Oncology University of Tor Vergata Rome

PROSTATE CANCER: LOCAL CONTROL, SURVIVAL AND HIGH DOSE RADIATION THERAPY. Riccardo Santoni. Radiation Oncology University of Tor Vergata Rome PROSTATE CANCER: LOCAL CONTROL, SURVIVAL AND HIGH DOSE RADIATION THERAPY Riccardo Santoni Radiation Oncology University of Tor Vergata Rome Problems: the epidemic prostate cancer and its implications USA

More information

Current status of HDR Brachytherapy for prostate cancer (in the UK) Paul Evans Memorial lecture. Peter Hoskin Mount Vernon Cancer Centre

Current status of HDR Brachytherapy for prostate cancer (in the UK) Paul Evans Memorial lecture. Peter Hoskin Mount Vernon Cancer Centre Current status of HDR Brachytherapy for prostate cancer (in the UK) Paul Evans Memorial lecture Peter Hoskin Mount Vernon Cancer Centre MVH RCT 55Gy/20f Ext beam 35.7Gy/13f + 17Gy/2f HDR Closed 08/05:

More information

Prostate Cancer Treatment: What s Best for You?

Prostate Cancer Treatment: What s Best for You? Prostate Cancer Treatment: What s Best for You? Prostate Cancer: Radiation Therapy Approaches I. Choices There is really a variety of options in prostate cancer management overall and in radiation therapy.

More information

Late results of the HyPro study (Hypofractionation in Prostate cancer patients) and clinical implications

Late results of the HyPro study (Hypofractionation in Prostate cancer patients) and clinical implications Late results of the HyPro study (Hypofractionation in Prostate cancer patients) and clinical implications Marjolein van Os, research technologist Erasmus MC Cancer Institute, Rotterdam, The Netherlands

More information

stereotactic body radiation therapy for liver

stereotactic body radiation therapy for liver protocol for cyberknife treatment of limited liver metastases PROTOCOL LIVER stereotactic body radiation therapy for liver CyberKnife delivers targeted, concentrated beams of radiation. Treatment Modalities

More information

Surgery for the treatment of localized prostate cancer

Surgery for the treatment of localized prostate cancer Surgery for the treatment of localized prostate cancer Joseph Dall Era Division of Urology November 24, 2008 General Surgery Grand Rounds University of Colorado Prostate Cancer Statistics 234,460 cases

More information

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma. Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of

More information

HealthEast Prostate Care. Annual Report 2010

HealthEast Prostate Care. Annual Report 2010 HealthEast Prostate Care Annual Report 2010 Prostate Cancer Overview More than 2 million men in the United States are prostate cancer survivors. Prostate cancer is the second most common type of cancer

More information

Target Delineation for Prostate Cancer

Target Delineation for Prostate Cancer Target Delineation for Prostate Cancer Michael J Zelefsky M.D. Professor of Radiation Oncology Chief, Brachytherapy Service Memorial Sloan Kettering Cancer Center Keys for Successful Contouring Familiarity

More information

Brachytherapy Physics. Prostate

Brachytherapy Physics. Prostate Brachytherapy Physics Prostate Prostate Brachytherapy Permanent Seed Prostate Brachytherapy (LDR) TG43 Data Physics guidelines require 10% seed assay Needle types Loose Seeds loaded manually into needles

More information

Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-risk Prostate Cancer

Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-risk Prostate Cancer The abstract of this paper is given below: Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-risk Prostate Cancer Christopher R. King, PhD, MD 1, James D. Brooks, MD

More information

Cyberknife Information Guide. Prostate Cancer Treatment

Cyberknife Information Guide. Prostate Cancer Treatment Cyberknife Information Guide Prostate Cancer Treatment CYBERKNIFE INFORMATION GUIDE PROSTATE CANCER TREATMENT As a patient recently diagnosed with localized prostate cancer, it is important that you familiarize

More information

Treatment options for men with localised prostate cancer

Treatment options for men with localised prostate cancer Treatment options for men with localised prostate cancer Choosing a treatment for prostate cancer is not easy. The primary choices include active surveillance, surgical removal of the prostate gland, radiation

More information

Brachytherapy: The precise answer for tackling prostate cancer. Because life is for living

Brachytherapy: The precise answer for tackling prostate cancer. Because life is for living Brachytherapy: The precise answer for tackling prostate cancer Because life is for living Table of contents Executive summary 3 Introduction 4 Overview of brachytherapy 5 Brachytherapy options for prostate

More information

Proton Therapy for Prostate Cancer

Proton Therapy for Prostate Cancer Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director, Proton Therapy Center Associate Professor Department of Radiation Oncology M.D. Anderson Cancer Center Randomized studies showing benefit

More information

Conformal Radiation Therapy of Prostate Cancer-What Can We Learn from the IMRT Experience?

Conformal Radiation Therapy of Prostate Cancer-What Can We Learn from the IMRT Experience? Conformal Radiation Therapy of Prostate Cancer-What Can We Learn from the IMRT Experience? Carl J. Rossi, JR., MD Associate Professor, Radiation Medicine Loma Linda University Medical Center Why study

More information

Chuxiong Ding, Ph.D., Cheng-Hui Chang, Ph.D., Joshua Haslam, Ph.D., Robert Timmerman, M.D., Timothy Solberg, Ph.D.

Chuxiong Ding, Ph.D., Cheng-Hui Chang, Ph.D., Joshua Haslam, Ph.D., Robert Timmerman, M.D., Timothy Solberg, Ph.D. Dosimetric comparison of SBRT for lung cancer: Cyberknife vs. Linac Chuxiong Ding, Ph.D., Cheng-Hui Chang, Ph.D., Joshua Haslam, Ph.D., Robert Timmerman, M.D., Timothy Solberg, Ph.D. Department of Radiation

More information

Radiotherapy Treatment Planning: Objectives, Formulations and Clinical Implications

Radiotherapy Treatment Planning: Objectives, Formulations and Clinical Implications Radiotherapy Treatment Planning: Objectives, Formulations and Clinical Implications Michael J Zelefsky M.D Memorial Sloan-Kettering Cancer Center New York, N.Y New Challenges for RT Treatment Planning

More information

22-Sep-16. Disclaimer who am I? An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan. Take home messages

22-Sep-16. Disclaimer who am I? An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan. Take home messages An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Sandra Turner Radiation Oncologist Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney Disclaimer who am I?

More information

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology

PROSTATE CANCER. Get the facts, know your options. Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology PROSTATE CANCER Get the facts, know your options Samay Jain, MD, Assistant Professor,The University of Toledo Chief, Division of Urologic Oncology i What is the Prostate? Unfortunately, you have prostate

More information

Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer

Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer ORIGINAL ARTICLE Acute Toxicity After CyberKnife-Delivered Hypofractionated Radiotherapy for Treatment of Prostate Cancer Natasa C. Townsend, MD,* Bradley J. Huth, MD,* William Ding, MD,* Bruce Garber,

More information

The Physical and Biological Basis of Radiation Therapy

The Physical and Biological Basis of Radiation Therapy The Physical and Biological Basis of Radiation Therapy David J. Brenner, PhD, DSc Center for Radiological Research Department of Radiation Oncology Columbia University Medical Center djb3@columbia.edu

More information

Radiation Therapy in Prostate Cancer Current Status and New Advances

Radiation Therapy in Prostate Cancer Current Status and New Advances Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Radiation Therapy Wilhelm Roentgen (1845-1923)

More information

Session Name: SABR Session

Session Name: SABR Session Session Name: SABR Session Presentation Title: The Role of Stereotactic Body Radiotherapy (SBRT) in the Treatment of Oligometastatic Prostate Cancer (PCa) Presenter Name: Nola Bailey Session Name: In accordance

More information

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate

More information

Impact of Intrafractional Prostate Motion on the Accuracy and Efficiency of Prostate Cancer Treatment on CyberKnife Radiotherapy

Impact of Intrafractional Prostate Motion on the Accuracy and Efficiency of Prostate Cancer Treatment on CyberKnife Radiotherapy Impact of Intrafractional Prostate Motion on the Accuracy and Efficiency of Prostate Cancer Treatment on CyberKnife Radiotherapy by Ricardo Eduardo De Armas SUBMITTED TO THE DEPARTMENT OF MECHCANICAL ENGINEERING

More information

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Dictionary Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Applicator A device used to hold a radioactive source

More information

2/14/09. Long Term Risk of Radiation Therapy for Clinically Localized Prostate Cancer. Radiation Therapy: Various Forms of Radiation Treatment

2/14/09. Long Term Risk of Radiation Therapy for Clinically Localized Prostate Cancer. Radiation Therapy: Various Forms of Radiation Treatment Radical ctomy (surgery) Mack Roach III MD Professor & Chair Department of Radiation Oncology Long Term Risk of Radiation Therapy for Clinically Localized Cancer Radiation Therapy: Hormonal Therapy Cryotherapy

More information

Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021 Introduction Prostate is one of the treatment sites that is well suited for IMRT. For

More information

LATE MORBIDITY PROFILES IN PROSTATE CANCER PATIENTS TREATED TO 79 84 GY BY A SIMPLE FOUR-FIELD COPLANAR BEAM ARRANGEMENT

LATE MORBIDITY PROFILES IN PROSTATE CANCER PATIENTS TREATED TO 79 84 GY BY A SIMPLE FOUR-FIELD COPLANAR BEAM ARRANGEMENT PII S0360-3016(02)03822-1 Int. J. Radiation Oncology Biol. Phys., Vol. 55, No. 1, pp. 71 77, 2003 Copyright 2003 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/03/$ see front matter

More information

Newly Diagnosed Prostate Cancer: Understanding Your Risk

Newly Diagnosed Prostate Cancer: Understanding Your Risk Newly Diagnosed Prostate Cancer: Understanding Your Risk When the urologist calls with the life-changing news that your prostate biopsy is positive for prostate cancer, an office appointment is made to

More information

Outline BT in IG-IMRT Era Evolution of medical practices: a Darwinian struggle Brachytherapy (BT) vs IMRT. Brachytherapy in the Image-guided IMRT Era

Outline BT in IG-IMRT Era Evolution of medical practices: a Darwinian struggle Brachytherapy (BT) vs IMRT. Brachytherapy in the Image-guided IMRT Era The Department of Radiation Oncology Brachytherapy in the Image-guided Era Jeffrey F. Williamson, Ph.D. and the Brachytherapy- Team M. Fatyga, N Dogan, M. Hagan, and D. Todor Outline BT in IG- Era Evolution

More information

Prostate Cancer Treatment

Prostate Cancer Treatment Scan for mobile link. Prostate Cancer Treatment Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam,

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

Coding for Prostate Cancer

Coding for Prostate Cancer Coding for Prostate Cancer Tracy L. Burney, M.D. Health First Physicians Urology September 19, 2012 Prostate Cancer Basics What is the Prostate and What Does it do? Walnut sized organ found only in men.

More information

Current and Future Trends in Proton Treatment of Prostate Cancer

Current and Future Trends in Proton Treatment of Prostate Cancer Current and Future Trends in Proton Treatment of Prostate Cancer Reinhard W. Schulte Assistant Professor Department of Radiation Medicine Loma Linda University Medical Center Loma Linda, CA, USA Outline

More information

Where We Came From Frame-Based Spine Radiosurgery: 1995

Where We Came From Frame-Based Spine Radiosurgery: 1995 Spine Radiosurgery John C Flickinger MD and Peter Gerszten MD Departments of Radiation Oncology and Neurological Surgery University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Where We Came From

More information

Therapies for Clinically Localized Prostate Cancer

Therapies for Clinically Localized Prostate Cancer 1 di 5 14/06/2016 15.53 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville

More information

Management of Localized Prostate Cancer. Treatment Options

Management of Localized Prostate Cancer. Treatment Options Management of Localized Prostate Cancer Surgery James A. Eastham, MD Chief, Urology Service Memorial lsloan Kettering Cancer Center Treatment Options 1. Active surveillance/watchful waiting 2. Focal therapy

More information

Stereotactic Radiotherapy for Prostate Cancer using CyberKnife

Stereotactic Radiotherapy for Prostate Cancer using CyberKnife Stereotactic Radiotherapy for Prostate Cancer using CyberKnife Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm

More information

This house believes that locally advanced prostate cancer should be treated with radiotherapy and hormone deprivation

This house believes that locally advanced prostate cancer should be treated with radiotherapy and hormone deprivation This house believes that locally advanced prostate cancer should be treated with radiotherapy and hormone deprivation AGAINST Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center

More information

Testosterone and Radiotherapy for Prostate Cancer

Testosterone and Radiotherapy for Prostate Cancer Testosterone and Radiotherapy for Prostate Cancer Luca Incrocci, MD, PhD Associate Professor of Radiation Oncology Erasmus MC Cancer Institute, Rotterdam, The Netherlands October 11th, 2014 Round Table

More information

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective

The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective The Business of Prostate Cancer Care: A Clinician-Researcher s Perspective David F. Penson, MD, MPH Departments of Urology and Preventive Medicine Keck School of Medicine University of Southern California

More information

Primary Management Options Evaluated for Low-Risk Prostate Cancer: A Case Study Using Comparative Effectiveness Research

Primary Management Options Evaluated for Low-Risk Prostate Cancer: A Case Study Using Comparative Effectiveness Research Primary Management Options Evaluated for Low-Risk Prostate Cancer: A Case Study Using Comparative Effectiveness Research Donald E. Casey, MD, MD, MPH, MBA, FACP Laura T. Pizzi, PharmD, MPH American College

More information

Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.

Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014. Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience Richard Pötter MD BrachyNext, Miami, 2014 Disclosures Richard Pötter, MD, does not have any financial relationships or

More information

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: 6.01.16 CATEGORY: Technology Assessment

MEDICAL POLICY. SUBJECT: BRACHYTHERAPY OR RADIOACTIVE SEED IMPLANTATION FOR PROSTATE CANCER POLICY NUMBER: 6.01.16 CATEGORY: Technology Assessment MEDICAL POLICY SUBJECT: BRACHYTHERAPY OR PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy

More information

Forum. Advances in radiation therapy for prostate. cancer. Abstract. Radiation therapy for localised prostate. cancer

Forum. Advances in radiation therapy for prostate. cancer. Abstract. Radiation therapy for localised prostate. cancer Advances in radiation therapy for prostate cancer Nitya Patanjali 1 and Scott Williams 2 1. Radiation Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney. 2. Radiation Oncology, Peter

More information

Prostate Cancer. Patient Information

Prostate Cancer. Patient Information Prostate Cancer Patient Information 1 The Prostate & Prostate Cancer The prostate is a small gland in the male reproductive system, approximately the size and shape of a walnut. It is located directly

More information

FAQ About Prostate Cancer Treatment and SpaceOAR System

FAQ About Prostate Cancer Treatment and SpaceOAR System FAQ About Prostate Cancer Treatment and SpaceOAR System P. 4 Prostate Cancer Background SpaceOAR Frequently Asked Questions (FAQ) 1. What is prostate cancer? The vast majority of prostate cancers develop

More information

KCE Report 194 & 226 Localised Prostate Cancer 1 1. ALGORITHM

KCE Report 194 & 226 Localised Prostate Cancer 1 1. ALGORITHM KCE Report 194 & 226 Localised Prostate Cancer 1 1. ALGORITHM 2 Localised Prostate Cancer KCE Report 194 & 226 2. RECOMMENDATIONS The scientific report with more background information and the methodological

More information

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology

Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Robotic Radical Prostatectomy: What s s the Advantage? Matthew T. Gettman, M.D. Associate Professor Department of Urology Prostate Cancer Epidemiology: 2009 Estimated new cases: 230,000 Estimated deaths:

More information

Fundamental Issues. Optimization for IMRT (I) - Fundamental Issues. Forward vs. Inverse Planning. Inverse Planning Is Less Forgiving

Fundamental Issues. Optimization for IMRT (I) - Fundamental Issues. Forward vs. Inverse Planning. Inverse Planning Is Less Forgiving Optimization for IMRT (I) - Fundamental Issues Ping Xia, Ph.D. University of California-San Francisco Fundamental Issues How many structures should be contoured? How to deal with overlapped structures?

More information

Radiation Therapy in Prostate Cancer Current Status and New Advances

Radiation Therapy in Prostate Cancer Current Status and New Advances Radiation Therapy in Prostate Cancer Current Status and New Advances Arno J. Mundt MD Professor and Chairman Dept Radiation Oncology Moores Cancer Center UCSD Presentation Welcome Overview of UCSD, Moores

More information

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives.

Understanding Prostate Cancer. The Urology Group Guide for Newly Diagnosed Patients. Advanced Care. Improving Lives. Understanding Prostate Cancer The Urology Group Guide for Newly Diagnosed Patients Advanced Care. Improving Lives. UNDERSTANDING PROSTATE CANCER The Urology Group has created this publication to provide

More information

3D-CRT Carcinoma Prostate. Dr. Vijay Anand P. Reddy Director Apollo Cancer Institute, Hyderabad

3D-CRT Carcinoma Prostate. Dr. Vijay Anand P. Reddy Director Apollo Cancer Institute, Hyderabad 3D-CRT Carcinoma Prostate Dr. Vijay Anand P. Reddy Director Apollo Cancer Institute, Hyderabad 3D-CRT in Ca Prostate Introduction Advantages in Ca-Prostate Steps of 3D-CRT in Ca Prostate Patient Positioning

More information

NIA RADIATION ONCOLOGY CODING STANDARD. Dosimetry Planning

NIA RADIATION ONCOLOGY CODING STANDARD. Dosimetry Planning NIA RADIATION ONCOLOGY CODING STANDARD Dosimetry Planning CPT Codes: 77295, 77300, 77301, 77306, 77307, 77321, 77316, 77317, 77318, 77331, 77399 Original Date: April, 2011 Last Reviewed Date: November,

More information

Brachytherapy for the Treatment of Prostate Cancer

Brachytherapy for the Treatment of Prostate Cancer Brachytherapy for the Treatment of Prostate Cancer Yakov Pipman, D.Sc. Long Island Jewish Medical Center Prostate Cancer grows slowly Clinical Considerations Early detection is more common Larger Doses

More information

CyberKnife Radiosurgery for Prostate Cancer

CyberKnife Radiosurgery for Prostate Cancer Technology in Cancer Research and Treatment ISSN 1533-0346 Volume 9, Number 5, October 2010 Adenine Press (2010) CyberKnife Radiosurgery for Prostate Cancer www.tcrt.org Treatment of prostate cancer with

More information

Proton Therapy for Prostate Cancer:

Proton Therapy for Prostate Cancer: Proton Therapy for Prostate Cancer: What is it Worth? Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10 th Annual Symposium

More information

Radiation Therapy Approaches in the Elderly

Radiation Therapy Approaches in the Elderly Radiation Therapy Approaches in the Elderly Dr Daniel Tan YH MBBS, FRCR (Clinical Oncology), FAMS (Radiation Oncology) Consultant, National Cancer Centre Singapore Introduction Main Interests: Stereotactic

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Dosimetry on the Intraoperative Procedure

Dosimetry on the Intraoperative Procedure LDR-Brachytherapy of Prostate Cancer: Impact of Post-Implant Dosimetry on the Intraoperative Procedure Dr. med. Armin Thöni Dr. phil. nat. Hans Neuenschwander PD Dr. med. Jörn Wulf Radio-Onkologie, Lindenhofspital

More information

Brachytherapy for prostate cancer

Brachytherapy for prostate cancer The Alberta Heritage Foundation for Medical Research Brachytherapy for prostate cancer Fiona Wills, David Hailey December 1999 HTA 17 Brachytherapy for prostate cancer Fiona Wills, David Hailey December

More information

London Cancer. Clinical Radiotherapy Guidelines for Carcinoma of the Bladder

London Cancer. Clinical Radiotherapy Guidelines for Carcinoma of the Bladder London Cancer Clinical Radiotherapy Guidelines for Carcinoma of the Bladder May 2014 Contents 1. Introduction... 3 1.1. Cancer definition...3 1.2. Stages...3 1.3. Indications...3 1.4. Intent...3 1.5. Timing

More information

Chapter 3. Treatment Options

Chapter 3. Treatment Options Chapter 3. Treatment Options With contributions from Nancy L. Brown, Ph.D., Palo Alto Medical Foundation Research Institute; Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program; D. Jeffrey Demanes,

More information

Focal therapy for prostate cancer: seriously or seriously? Disclosures

Focal therapy for prostate cancer: seriously or seriously? Disclosures Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium

More information

Quality of Life After Radical Prostatectomy

Quality of Life After Radical Prostatectomy Quality of Life After Radical Prostatectomy Bernard H. Bochner, MD FACS Attending Surgeon, Urology Service Vice Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center Quality of Life After

More information

Are you living with Prostate Cancer?

Are you living with Prostate Cancer? People in Partnership Meeting (PIP) Are you living with Prostate Cancer? And want to know how to manage it? Mr Alvan Pope, Consultant Urologist at Hillingdon and Mount Vernon Hospitals speaking to patients

More information

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy)

da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) da Vinci Prostatectomy Information Guide (Robotically-Assisted Radical Prostatectomy) Prostate Cancer Overview Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the

More information

What is the CyberKnife System?

What is the CyberKnife System? CYBERKNIFE Robotic Radiosurgery System PATIENT BROChURE 1 What is the CyberKnife System? have stabilizing frames bolted to their head or limit their breathing during treatment to minimize movement of the

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo

Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo Esperienza di stereotassia polmonare al Campus Bio-Medico: tecnica e risultati Rolando M. D Angelillo Università Campus Bio-Medico di Roma - Via Álvaro del Portillo, 21-00128 Roma Italia BED 10 > 100 Gy

More information

DOCTOr. Doctor to HIGHLIGHTS. issue NO. 3 VOLuMe NO. 1

DOCTOr. Doctor to HIGHLIGHTS. issue NO. 3 VOLuMe NO. 1 Doctor to DOCTOr issue NO. 3 VOLuMe NO. 1 PROSTATE CANCER is the most common cancer in men, with 233,000 new cases diagnosed per year. Although prostate cancer remains the second leading cause of cancer

More information

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative. Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean

More information

Prostate Cancer. Michael Lock MD CCFP FRCPC Glenn Bauman MD FRCPC Michael Sanatani MD FRCPC Last updated: July 2010

Prostate Cancer. Michael Lock MD CCFP FRCPC Glenn Bauman MD FRCPC Michael Sanatani MD FRCPC Last updated: July 2010 Prostate Cancer Michael Lock MD CCFP FRCPC Glenn Bauman MD FRCPC Michael Sanatani MD FRCPC Last updated: July 2010 What is the chance of a male developing prostate cancer? What is the chance of dying of

More information

Principles of Radiation Therapy

Principles of Radiation Therapy Principles of Radiation Therapy Peter B. Schiff, M.D., Ph.D. Department of Radiation Oncology Columbia University College of Physicians & Surgeons May 4, 2007 Targeted Therapy in Oncology Surgical Oncology

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS FOR

More information

In intermediate-high risk endometrial cancer loco-regional control is improved by radiation therapy

In intermediate-high risk endometrial cancer loco-regional control is improved by radiation therapy TRATTAMENTO ADIUVANTE DEL CARCINOMA DELL ENDOMETRIO: STUDIO PROSPETTICO DI IRRADIAZIONE DELLA PELVI CON SOVRADOSAGGIO SIMULTANEO SULLA CUPOLA VAGINALE CON TECNICA VOLUMETRICA AD INTENSITA MODULATA IN ALTERNATIVA

More information

IMRT for Prostate Cancer. Robert A. Price Jr., Ph.D. Philadelphia, PA

IMRT for Prostate Cancer. Robert A. Price Jr., Ph.D. Philadelphia, PA IMRT for Prostate Cancer Robert A. Price Jr., Ph.D. Philadelphia, PA Number of Patients 16 14 12 1 8 6 4 1481 IMRT Patients at FCCC 293 97 Prostate Breast H&N Other 64 Approximately 13-15 patients per

More information

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific

More information

SAFE AND INNOVATIVE RADIATION THERAPY. Advanced treatment options including the CyberKnife System

SAFE AND INNOVATIVE RADIATION THERAPY. Advanced treatment options including the CyberKnife System SAFE AND INNOVATIVE RADIATION THERAPY Advanced treatment options including the CyberKnife System Surgery-Free Cancer Treatment in Suffolk County If you need treatment for cancer or non-cancerous tumors,

More information

Greater Manchester and Cheshire Cancer Network PROSTATE CANCER GUIDELINES

Greater Manchester and Cheshire Cancer Network PROSTATE CANCER GUIDELINES Greater Manchester and Cheshire Cancer Network PROSTATE CANCER GUIDELINES Agreed by Urology CSG: July 2010 Review Date: July 2012 PROSTATE CANCER 1 INITIAL REFERRAL FROM GP GPs will follow the existing

More information

馬 偕 紀 念 醫 院 新 竹 分 院 前 列 腺 癌 放 射 治 療 指 引

馬 偕 紀 念 醫 院 新 竹 分 院 前 列 腺 癌 放 射 治 療 指 引 馬 偕 紀 念 醫 院 新 竹 分 院 前 列 腺 癌 放 射 治 療 指 引 2009.12.02 修 訂 2013.05.13 四 版 前 言 新 竹 馬 偕 醫 院 放 射 腫 瘤 科 藉 由 跨 院 聯 合 會 議 機 制 進 行 討 論, 以 制 定 符 合 現 狀 之 前 列 腺 癌 放 射 治 療 指 引 本 院 前 列 腺 癌 放 射 治 療 指 引 的 建 立, 係 參 考 國 內

More information

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer

Prostate Cancer Guide. A resource to help answer your questions about prostate cancer Prostate Cancer Guide A resource to help answer your questions about prostate cancer Thank you for downloading this guide to prostate cancer treatment. We know that all the information provided online

More information

Gamma Knife and Axesse Radiosurgery

Gamma Knife and Axesse Radiosurgery Gamma Knife and Axesse Radiosurgery John C Flickinger MD Departments of Radiation Oncology & Neurological Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania Origin of Radiosurgery

More information

PSA Screening for Prostate Cancer Information for Care Providers

PSA Screening for Prostate Cancer Information for Care Providers All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits

More information

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD

PROSTATE CANCER UPDATE. Presenter: Bruce W. Porterfield, MD, PhD PROSTATE CANCER UPDATE DISCLOSURES I, BRUCE WAYNE PORTERFIELD HAVE NOTHING TO DISCLOSE. OBJECTIVES Epidemiology Early detection and screening Review of clinical disease states Treatment options by disease

More information

Michael J. Zelefsky,*, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy and Howard Amols

Michael J. Zelefsky,*, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy and Howard Amols Long-Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer Michael J. Zelefsky,*, Heather Chan, Margie Hunt, Yoshiya Yamada, Alison M. Shippy

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2016 PQRS OPTIONS

More information

Technology Assessment

Technology Assessment Technology Assessment Technology Assessment Program Comparative evaluation of radiation treatments for clinically localized prostate cancer: an update Prepared for: Agency for Healthcare Research and Quality

More information